Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Current Assets: 2019-2025

Historic Current Assets for Revolution Medicines (RVMD) over the last 6 years, with Sep 2025 value amounting to $2.0 billion.

  • Revolution Medicines' Current Assets rose 25.23% to $2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 billion, marking a year-over-year increase of 25.23%. This contributed to the annual value of $2.3 billion for FY2024, which is 23.86% up from last year.
  • Latest data reveals that Revolution Medicines reported Current Assets of $2.0 billion as of Q3 2025, which was down 9.14% from $2.2 billion recorded in Q2 2025.
  • Over the past 5 years, Revolution Medicines' Current Assets peaked at $2.3 billion during Q4 2024, and registered a low of $483.0 million during Q2 2022.
  • For the 3-year period, Revolution Medicines' Current Assets averaged around $1.6 billion, with its median value being $1.7 billion (2024).
  • In the last 5 years, Revolution Medicines' Current Assets fell by 26.92% in 2022 and then spiked by 184.66% in 2023.
  • Quarterly analysis of 5 years shows Revolution Medicines' Current Assets stood at $589.8 million in 2021, then rose by 11.94% to $660.2 million in 2022, then surged by 184.66% to $1.9 billion in 2023, then rose by 23.86% to $2.3 billion in 2024, then rose by 25.23% to $2.0 billion in 2025.
  • Its Current Assets was $2.0 billion in Q3 2025, compared to $2.2 billion in Q2 2025 and $2.1 billion in Q1 2025.